摘要
目的系统评价中性粒细胞与淋巴细胞比值(NLR)对接受立体定向放疗(SBRT)的非小细胞肺癌(NSCLC)患者预后的预测价值。方法通过检索PubMed、Embase、Cochrane和Web of Science数据库中关于NLR和接受SBRT治疗的NSCLC预后的全部研究,筛选出符合标准的研究。以总生存期(OS)和无病发生存期(DFS)为观察终点,其风险比(HR)及95%可信区间(CI)作为效应变量,利用meta分析合并HR和95%CI以评估预后价值。通过逐一剔除法评估结果稳健性。利用漏斗图、Egger及Begg检验评价发表偏倚。结果7项回顾性队列研究包含1621例NSCLC患者被纳入分析,结果显示,放疗前NLR升高的患者其OS(HR=1.48,95%CI 1.22~1.80,P=0.030)和DFS(HR=1.16,95%CI 1.02~1.32,P=0.028)较差。灵敏度分析结果显示有较好的稳定性。发表偏倚评价提示未存在明显偏倚。结论NLR可作为NSCLC患者SBRT治疗方便、较准确的预后指标。
Objective To systematically evaluate the prognostic value of neutrophil to lymphocyte ratio(NLR)in patients with non-small cell lung cancer(NSCLC)undergoing stereotactic body radiotherapy(SBRT).Methods All studies on the prognosis of NSCLC treated with NLR and SBRT were searched in PubMed,Embase,Cochrane and Web of Science databases.Overall survival(OS)and disease-free survival(DFS)were used as endpoints,with hazard ratio(HR)and 95%confidence interval(CI)as effect variables.Meta-analysis combined HR and 95%CI was used to evaluate prognostic value.The robustness of the results was evaluated by one-by-one elimination method.Funnel plot,Egger and Begg tests were used to evaluate publication bias.Results Totally,7 retrospective cohort studies with 1621 NSCLC cases were included.The results showed that patients with elevated NLR before radiotherapy had poorer OS(HR=1.48,95%CI 1.22-1.80,P=0.030)and DFS(HR=1.16,95%CI 1.02-1.32,P=0.028).The sensitivity analysis results show that it has good stability.Publication bias evaluation suggested that there was no significant bias.Conclusion NLR can be considered as a convenient and reliable biomarker for predicating the outcomes in NSCLC patients who received SBRT.
作者
解啸明
孙恒亮
XIE Xiaoming;SUN Hengliang(Clinical Laboratory,Haian Hospital of Traditional Chinese Medicine,Nantong 226600,China)
出处
《河南医学研究》
CAS
2023年第17期3113-3117,共5页
Henan Medical Research
